Allyx Therapeutics aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases.

Allyx Therapeutics

Allyx Therapeutics | 834 followers on LinkedIn. Protecting Synapses and Reversing Neurodegeneration | Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer&#39;s and Parkinson&#39;s disease by targeting the underlying cause of synapse dysfunction and loss.

Chief Financial Officer - EvolveImmune Therapeutics

Jennifer Gabler

Another pre-clinical tour de force from our colleagues at Yale School of Medicine demonstrating the effect of our lead drug ALX-001 (BMS-984923) on reversing functional connectivity deficits in an #Alzheimers Disease model. Yale Ventures https://lnkd.in/eZqPqW5x

We are honored to receive this grant from the National Institutes of Health Small Business Innovation Research Program (NIH SBIR) as we continue to advance ALX-001 as a potential first-in-class disease-modifying oral therapy in Alzheimer's disease and Parkinson's disease. https://lnkd.in/eT-4bEEA

Thanks to the Alzheimer's Association® for hosting such an incredible #WalktoEndAlzheimers at Lighthouse Point in New Haven yesterday. We were happy to show our support for the community and remember our goal of helping the patients and families living with this disease. #EndAlz

We are thrilled to announce a significant milestone in our journey to combat #Parkinsons disease, the dosing of our first #PD patient in a Phase 1b 28-day repeat dose clinical study. This marks an important next step in our commitment to developing our innovative therapy, ALX-001, to provide a meaningful impact on the lives of those affected by neurodegenerative diseases. This has been a true collaborative effort with our funding partners at The Michael J. Fox Foundation for Parkinson's Research and the clinical team at the Duke Clinical Research Institute . We also extend our gratitude to the patients, families, and partners who have placed their trust in our mission. Stay tuned for more updates as we continue to advance our research and strive towards a brighter future for Parkinson's disease patients. #Biotech #ClinicalTrials #ParkinsonsDisease #Innovation #Healthcare https://lnkd.in/dq5NQWNd

Another nice feature on our efforts to continue advancing ALX-001 for patients with #Alzheimers Disease. https://lnkd.in/eqNEmmwd

What better timing than during June's #Alzheimer 's & Brain Awareness Month than to announce our first #AD patients began treatment with ALX-001, the latest milestone for our team at Allyx Therapeutics . While there has been great progress with anti-amyloid monoclonal therapies and likely an additional commercial treatment option on the way, Alzheimers's will continue to be a major unmet need with patients and families needing more efficacious, safer, and more convenient treatments. This is just the latest milestone in our journey to develop a better and oral treatment for AD. Thanks to all those supporting Allyx Therapeutics in our journey including our investors and grant funders ( National Institute on Aging (NIA) , Alzheimer's Association® , and The Michael J. Fox Foundation for Parkinson's Research ). An additional special thanks to the patients and their families for their participation and enthusiasm. #ENDALZ https://lnkd.in/edPdEkYP

Proud to be recognized by Senator Murphy as April's "Innovator of the Month" for our work in #Alzheimer 's and #Parkinson 's disease and as an example of the thriving #biotech ecosystem here in Connecticut! https://lnkd.in/gCy9WKNc

Immensely grateful to the The National Institutes of Health and The Michael J. Fox Foundation for Parkinson's Research for their continued support of our ALX-001 program and receiving authorization from the FDA on our latest IND in #parkinsonsdisease . https://lnkd.in/ekPb2_5q

Thanks to the Yale Ventures and Biohaven teams for hosting an excellent event at #jpm2024 . Always an honor to share our story and be part of such a strong Connecticut #biotech ecosystem.

Viewport Meta

IPhone / Mobile Compatible

nginx

Microsoft Exchange Online

DMARC

Office 365 Mail

Google

Google Cloud

Microsoft Azure DNS

Chief Operating Officer

Timothy Siegert

Paul Fonteyne

Stephen Bloch

Co-Founder and CEO

Stephen M. Strittmatter

Co-Founder

Co-Founder and Advisor

Health Care Companies With Fewer Than 10 Employees (Top 10K)

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

New England Life Science Companies

East Coast Companies With Fewer Than 100 Employees (Top 10K)

Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug capable of delivering a disease-modifying approach and preserving cognition in patients.

National Institutes of Health

Grant - Allyx Therapeutics

Venture Round - Allyx Therapeutics

Series A - Allyx Therapeutics

Convertible Note - Allyx Therapeutics

New Haven

Connecticut

United States

North America

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001

Allyx Therapeutics Announces First Alzheimer's Disease

FDA OKs clinical research application for new Parkinson's drug from New Haven-based Allyx Therapeutics

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Parkinson's clinical trial of ALX-001 DMT to start by month's end

An orally bioavailable and brain-penetrant small molecule that acts as a silent allosteric modulator of mGluR5, aimed at treating neurodegenerative diseases by selectively blocking pathogenic activation while preserving normal glutamate signaling.

A clinical study evaluating the safety, tolerability, pharmacokinetics, and receptor occupancy of ALX-001.

A food effect study of ALX-001 in healthy older adults.

A multiple ascending dose study in healthy volunteers and patients with Alzheimer’s disease.

news impact assignment basic	general
public peers	general	Nov 15, 2024 10:34 AM	e8cbc29f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 15, 2024 10:34 AM	0b4ea385
crunchbase trigger	general	Nov 15, 2024 10:34 AM	d6b43f74
crunchbase profile	general	Nov 15, 2024 7:14 PM	2a8ff687
li profile	general	Nov 15, 2024 10:34 AM	d175eb0e
translate crunchbase fundingrounds	general	Nov 15, 2024 7:44 PM	c0b212ae
peers	general	Nov 15, 2024 10:34 AM	085284b5
news basic	general	Nov 15, 2024 10:34 AM	1ec9fb3e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ALLY

COM:ALLYXTHERA

Allyx Therapeutics